PROSPER: Prospective Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin-α (TARGAXAN/XIFAXAN) 550 mg

Trial Profile

PROSPER: Prospective Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin-α (TARGAXAN/XIFAXAN) 550 mg

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Feb 2016

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Hepatic encephalopathy
  • Focus Therapeutic Use
  • Acronyms PROSPER
  • Sponsors Norgine
  • Most Recent Events

    • 10 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 06 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top